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Introduction 
Transcutaneous electrical nerve stimulation (TENS) is a non-invasive modality 
commonly used in rehabilitation for pain relief [20]. Scientific rationale behind low-
intensity/ high-frequency TENS (also known as conventional-mode TENS) is generally 
based on the gate-theory proposed by Melzack and Wall [19] where stimulation of non-
nociceptive afferents (A fibers) inhibit the nociceptive signal transmitted by Aδ and C 
fibers.  The release of endogenous opioids following high-frequency TENS application 
has also been proposed as a possible mechanism of action [9;22].  This latter premise 
was, however, refuted by the work of several authors who showed that the analgesic 
properties of high-frequency TENS could not be reversed by the opioid antagonist 
naloxone [1;10;13;14;17;24;29]. 
Recently, Sluka and colleagues [15;25] have re-examined the role of endogenous 
opioids in the analgesia induced by high-frequency TENS.  Using a kaolin and 
carrageenan joint inflammation model in Sprague-Dawley rats, they showed that spinal 
[25] and supraspinal [15] blockade of δ opioid receptors with naltrindole reversed high-
frequency TENS analgesia.  They also reported that high doses of naloxone (blocking the 
, δ and  opioid receptors) prevented the antihyperalgesic effects produced by high-
frequency TENS whereas lower doses of naloxone (blocking only the  opioid receptors) 
did not reversed the effect of high-frequency TENS [25].  These results lead to the 
conclusion that the analgesia induced by high-frequency TENS was mediated by δ 
receptors and that failure of naloxone to reverse high-frequency TENS analgesia in 
previous studies was due to the inability of the antagonist to block δ receptors with the 
low doses used. 
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Based on these results from animal studies, the purpose of this study was to 
reinvestigate the implication of opioid receptors in the analgesia induced by high-
frequency TENS in human subjects by using high (0.14 mg/kg) and low (0.02 mg/kg) 
doses of naloxone.  Considering the work of Sluka and colleagues [15;25] and based on 
previous naloxone studies in humans [1;10;13;14;17;24;29], we hypothesized that the 
high – but not the low – dose of naloxone would reverse the analgesia induced by high-
frequency TENS. 
 
Methods 
Participants 
Twenty-one healthy volunteers (mean age 25.2 ± 6.0 years; 12 males) participated 
in the study.  None of the participants suffered from any known diseases and none took 
medications.  The experiment took place at the Clinical Research Centre of the 
Sherbrooke University Hospital, Sherbrooke, Quebec, Canada.   Subjects were recruited 
through local ads and were all French speaking community-dwelling individuals.  The 
local Institutional Ethics Committee approved the study’s procedures and each participant 
provided informed consent before participation. 
 
Tonic heat pain model 
Participants were seated comfortably in a reclining chair.  Before each session, a 
pre-testing session was first provided in order to familiarize participants with the 
computerized visual analogue scale (COVAS; Medoc, Advanced Medical Systems, 
Minneapolis) and to determine the temperature which would be used during the two 
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minutes pain test.  This pre-test was performed with a 1 cm2 Peltier-type thermode 
(Medoc, Advanced Medical Systems, Minneapolis) applied on the lateral surface of the 
left forefoot.  Participants were advised that the thermode temperature would gradually 
increase from 32° C to 51° C (rising rate = 0.3° C/s). The pre-test was repeated twice 
during which the subjects reported verbally their pain threshold and pain tolerance 
threshold.  On the third pre-test, subjects were given the COVAS and advised that they 
would have to start moving the cursor towards to right (towards the “100” mark) when 
they started to feel pain (pain threshold) and that the cursor had to be at the extreme right 
(at the “100” mark) when pain was intolerable (pain tolerance). This procedure was 
repeated until the subject's pain reports were consistent between trials. The temperature 
used during the following experimental heat pain test was determined by selecting the 
temperature for which the subject had rated the pain intensity at 50/100 with the COVAS 
(see Tousignant-Laflamme et al. [27] for a similar approach). 
Following the pre-test, participants were given a 10 minute rest period before the 
experimental test began.  The tonic pain test was then performed with the application of 
the thermode at constant temperature applied on the lateral aspect of the left heel for 2 
min.  Subjects were told that the thermode temperature could rise, remain stable or 
decrease and that they would have to evaluate their pain with the COVAS throughout the 
2 min test. In fact, after a constant rise (0.3° C/s) from baseline (32° C) to the 
individually predetermined temperature, the thermode's temperature remained constant 
throughout the 120 seconds. 
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TENS stimulation protocol 
For each visit, TENS stimulations were delivered using a pair of electrodes 
(rubber silicone, 4 x 4 cm) connected to a digital Eclipse Plus apparatus (Empi, St-Paul, 
Minnesota).  Electrodes were placed over the lateral aspect of the foot, above and below 
the area to be stimulated by the thermode.  More specifically, the cathode was positioned 
proximally near and above the malleolus and the anode was placed distally near the fifth 
metatarsal’s tuberosity (see Figure 1).  With the frequency set at 100 Hz and the pulse 
duration at 60 s, the stimulator’s intensity was adjusted to produce a strong and 
comfortable tingling sensation in the territory innervated by the sural nerve.  The 
experimenter made sure that the paresthesias were non-painful and covered adequately 
the lateral aspect of the heel.  In cases where stimulation did not cover properly the 
region, the stimulator was turned OFF and the electrodes repositioned.  The stimulation 
was applied for 25 minutes and the intensity was occasionally raised (based on the 
participant’s sensation) to account for nerve accommodation and to maintain the same 
level of paresthesias. 
 
Experimental design 
Volunteers were randomly assigned in a triple-blind, cross-over design to one of 
the following conditions: (1) high dose of naloxone (0.14 mg/kg), (2) low dose of 
naloxone (0.02 mg/kg) and (3) saline (0.9% NaCl).  Randomization (controlling for 
presentation order) was made using Minitab Statistical Sotfware (version 15.0 for 
Windows, State College, PA, USA).  Controlling for presentation order ensured that an 
equal number of participants were randomized to each possible permutation level.  All 
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injections had an equivalent volume and were administered by a registered nurse using an 
intravenous catheter inserted in the right forearm.  The naloxone dosage (0.14 mg/kg) 
was chosen because it has been used successfully in previous studies to completely 
antagonize endogenous opioid-mediated analgesia in healthy volunteers [2;4] and 
because it is believed to ensure adequate blockage of all opioid receptor subtypes [3;5].  
Because of naloxone’s short half-life (c. 30-40 min), all injections (including saline) were 
administered twice during the session (approx. 35 minutes interval).  This ensured that 
naloxone maintained its full effect throughout the testing session.  The experimenter, 
nurse and participant were blinded to the substance being injected.  Every participant was 
submitted to the three conditions (high dose of naloxone, low dose of naloxone, saline) in 
three consecutive sessions (approx. 120 minutes, 1 week interval between each visit).  
Each time, the tonic heat pain test was performed on four occasions: (1) at baseline (i.e. 
10 minutes after the pre-testing session), (2) after injection (naloxone or saline), (3) 
during TENS (i.e. 5 minutes prior to the end of TENS stimulation) and (4) 10 minutes 
after TENS application. 
Data analysis 
To facilitate comparisons, pain intensity ratings obtained during the 2 minute 
stimulation test were averaged and the mean was used in subsequent analysis.  Because 
of the relatively small number of subjects included in the study (n<30) and since visual 
inspection of the histograms did not allow us to assume that the data were normally 
distributed, non-parametric tests were employed.  Differences were considered to be 
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significant if p < 0.05 was obtained.  All tests were performed using SPSS (version 13.0 
for Windows®, Chicago, IL, USA).   
 
Results 
Conditioning effect 
Between-subject analyses were first performed to determine if the order of 
presentation affected the pattern of results obtained.  To do this, delta pain scores 
representing pain reductions experienced during TENS stimulation for the saline 
condition (delta pain score for saline = pain at baseline  – pain during TENS) were 
calculated and compared between (i) participants who received saline at their first 
session, (ii) participants who received saline at their second session (after having received 
a high or a low dose of naloxone at their first session) and (iii) participants who received 
saline at their third session (after having received naloxone at their first and second 
session). 
Figure 2 illustrates the analgesic effect of TENS obtained during stimulation for 
the saline condition between the three groups.  As it can be seen from the figure, the large 
analgesic effect of TENS observed in participants who received saline at their first visit 
was almost completely absent in participants who received saline after having received 
naloxone.  These differences were confirmed by the Kruskall-Wallis Test (p<.05) and by 
the post-hoc Mann-Whitney test which revealed a significant difference between 
participants who received saline at their first session and participants who received 
naloxone at their first and second sessions and saline at their third session (p<.01).  
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Effect of naloxone on TENS analgesia 
Since the order of presentation greatly affected the pattern of results and because 
we did not want our results to be contaminated by carry-over effects, we analysed the 
first testing session only.  To compensate for the lower power of the new analyses 
compared with the intended cross-over design analyses, three other participants were 
recruited (new sample = 24 healthy volunteers, mean age 24.9 ± 5.7 years; 13 males).  
These three participants were submitted to the same experimental protocol described 
above except that they took part in only one testing session (i.e. the first testing session).  
The pain intensity ratings obtained at baseline showed that every participant 
experienced pain (all pain measures at baseline   31).  Thermode temperatures and 
TENS stimulation intensities for all three conditions (at session 1 only) are showed in 
Table 1.  The Kruskall-Wallis Tests revealed that there were no significant differences in 
any of these parameters across the three groups (all p-values  .38).   
The average pain intensity obtained at baseline, post-injection, during TENS and 
post-TENS are presented in Figure 3.  As it can be seen from this figure, the high dose of 
naloxone – but not the low dose – blocked the analgesic effect of TENS seen during the 
saline condition.  Our Friedman’s Tests confirmed that there was a large and significant 
change in pain intensity across the different time measures for the saline (p<.001, η2=.90) 
and low dose group (p<.05, η2=.78) but not for the high dose group (p=.20, η2=.66).  
Post-hoc Wilcoxon Tests showed that there was a significant reduction in pain intensity 
both during and after TENS when compared with baseline for the saline (all p-values 
=.01) and low dose group (all p-values <.05).  There was no difference between the pain 
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measures obtained at baseline and the pain measures obtained 10 minutes after the 
injection (all p-values >.23). 
Between-subject analyses across the three groups using Kruskall-Wallis Tests 
revealed significant differences for pain intensity during TENS (p<.05) but not for the 
other time measures (baseline, post-injection and post-TENS, all p-values >.63), 
suggesting that naloxone only had an effect when TENS was applied.  Post-hoc Mann-
Whitney Tests comparing pain intensity during TENS showed that there was a significant 
difference between the saline group and the high dose group (p<.01).  There was no 
difference between the saline group and the low dose group (p=.08) and between the low 
dose group and high dose group (p=.12). 
 
Discussion 
In this study, we sought to determine if naloxone could reverse the analgesia 
induced by high-frequency TENS.  Our results showed that the high – but not the low – 
dose of naloxone blocked high-frequency TENS analgesia, hence providing the first 
evidence that the analgesia induced by high-frequency TENS in humans is mediated by 
opioid receptors. 
For several years and until recently, high-frequency TENS was believed to be 
non-opioidergic.  This supposition was based on numerous studies [1;10;13;14;17;24;29] 
which revealed that the analgesic properties of high-frequency TENS could not be 
reversed by low doses of naloxone.  On the opposite, other reports showed that the same 
doses of naloxone could block the analgesic effect of low-frequency/ high-intensity 
TENS (also-called acupuncture-like TENS) [7;17;23;29] leading to the premise that low-
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frequency TENS analgesia was produced via mechanisms utilizing endogenous opioids 
whereas high-frequency TENS analgesia was mediated via some other mechanism [24].  
Recently, Sluka et al. [25] challenged this long-standing belief by showing that high-
frequency TENS analgesia in Sprague-Dawley rats could be reversed by the opioid 
antagonist naloxone but that this required higher doses than what was necessary to 
reverse low-frequency TENS analgesia.  They also showed that selective blockade of δ 
opioid receptors with naltrindole reversed the analgesia induced by high-frequency 
TENS.  Sluka et al. interpreted these findings as an indication that high and low-
frequency TENS analgesia were mediated by different opioid receptors, with low-
frequency TENS producing analgesia through μ opioid receptors and high-frequency 
TENS producing analgesia through δ opioid receptors.  Indeed, the affinity of naloxone 
for δ opioid receptors is lower than that for μ opioid receptors [11], and it is likely that 
the inability to reverse high-frequency TENS analgesia in previous human studies 
[1;10;13;14;17;24;29] be attributable to the fact that the doses used were insufficient to 
antagonize the δ opioid receptors.  Unfortunately, no human studies followed the work of 
Sluka and colleagues and it was impossible, until today, to confirm that high-frequency 
TENS analgesia was opioid-mediated in humans.  Our results corroborate and extend the 
findings of Sluka et al. by showing that high-frequency TENS analgesia in humans can 
be reversed by high doses of naloxone.  They are also coherent with the results of 
previous human studies which showed that low naloxone doses not reverse high-
frequency TENS analgesia [1;10;13;14;17;24;29].  Manifestly, the insufficient amount of 
opioid antagonist prevented previous human studies from discovering the importance of 
opioid receptors in producing high-frequency TENS analgesia. 
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These results have several important implications.  First, they allow a better 
understanding of the mechanisms of action of TENS, providing the neurophysiological 
basis for the utilisation of TENS in clinic.  They also open interesting therapeutic 
considerations.  For instance, the involvement of opioid receptors in TENS analgesia 
suggests the existence of a possible interaction between TENS and oral opioid use.  
Animal evidence already support such a hypothesis, with studies showing (i) that animals 
rendered tolerant to high and low-frequency TENS are tolerant to δ and μ opioid agonists, 
respectively [6], and (ii) that rats tolerant to morphine are also tolerant to low-frequency 
TENS [26].  Future studies are necessary to determine if the interaction found in rodents 
between TENS and oral opioid use is also present in humans. 
Conditioning effect 
One important observation was that the analgesic effect of TENS stimulation 
(measured during the saline condition) was stronger when the saline was given during the 
first session than when it was given during the second or third session.  Pre-exposition to 
ineffective TENS treatment (in this case because of prior opioid blockade with naloxone) 
would hence reduce the efficacy of subsequent stimulation, even if given several days 
later in the absence of opioid blockade.  This phenomenon, which is probably due to a 
conditioning effect where exposition to unsuccessful procedures reduce the efficacy of 
subsequent ones, has already been observed in a study by Charron et al. [8] for placebo 
analgesia.  In the present study, we show that this conditioning effect can not only 
decrease the efficacy of placebo treatments but also the efficacy of genuine interventions 
(i.e. TENS treatment). 
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Although exploratory, these results have two important implications.  First, they 
suggest that the analgesic effect of TENS was underestimated in our participants who 
previously received naloxone.  This shortcoming brought us to discard the intended 
cross-over design analyses and to retain only the first visit of every participant.  Because 
this conditioning effect is susceptible to occur in other research situations, researchers 
should be cautious when they choose to use cross-over designs.  Moreover, and from a 
clinical perspective, these observations would entail that prior exposition to ineffective 
treatments (for example ineffective TENS applications because of inadequate electrode 
positioning or because of prior caffeine consumption [18]) would significantly reduce the 
analgesic efficacy of subsequent treatments.  This kind of observation evidently reminds 
the clinician about the importance of maximizing the efficacy of the first treatment.  
Future research aimed specifically at evaluating the interaction between the analgesic 
effect of a treatment and the previous experience of the patient with this treatment is 
needed. 
 
Limitations 
 On potential limitation of the present study is that TENS intensity was 
systematically raised during the stimulation period to maintain the same level of 
parasthesias.  Even though this might seem problematic, increasing TENS intensity 
during stimulation is a common procedure performed in clinic to compensate for nerve 
accommodation [21;28].  Most importantly however, this procedure can not account for 
the pattern of results obtained.  That is, we observed a reduction in TENS analgesia 
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during the high dose condition despite the fact that we raised TENS intensity (a 
procedure which is thought to potentiate TENS analgesia [21]). 
Perhaps another important criticism that could be addressed to the present study is 
the use of an experimental pain paradigm rather than a clinical pain paradigm.  Indeed, 
several of the previous studies looking at the interaction between high-frequency TENS 
and naloxone employed clinical pain paradigms [1;10;13;14;17;24] and some could 
wonder if the results of this study (based on pain ratings obtained on healthy volunteers 
during prolonged heat stimulation) would also have been obtained in pain patients.  
Without refuting the fact that experimental pain paradigm have less external validity than 
clinical pain paradigms, one has to remember that the former has on the counterpart the 
advantage of increasing the internal validity due to the constant stimulation parameters 
employed at each time measure.  In contrast, clinical pain conditions (even if fairly 
stable) can fluctuate throughout an experimental session, thus decreasing internal 
validity.  Nevertheless, the decision to recruit healthy volunteers rather than clinical pain 
patient was above all based on ethical reasons.  Indeed, high doses of naloxone have been 
shown to increase clinical pain in some patients [12;16]. 
One more limitation concerns the relatively low power of the analyses comparing 
pain scores between the low dose group and the other groups.  In fact, power calculation 
revealed that comparison between the low dose and the saline group reached a power of 
38% and that comparison between the low dose and high dose group reached a power of 
41%.  Alternately, comparison between the high dose and saline reached appropriate 
statistical power (1-β = 89%).  Although increasing the sample size may reveal 
significant effects when comparing the low dose condition to all other conditions, it 
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should not affect the dose-response relationship identified here. We believe this dose-
response relationship results from fundamental inter-condition differences in effect size, 
not sample size.  This is further confirmed by the index of effect size provided (see 
Results section).  Evidence of a dose response relationship is also consistent with the idea 
that naloxone is a non-specific antagonistic which incrementally affects opioid receptors 
[11]. 
Finally, it should be pointed out that the present study does not allow us to 
identify which opioid receptor (, δ or ) mediated TENS analgesia.  Even though the 
observations made on Sprague-Dawley rats by the group of Sluka and colleagues using 
the selective opioid antagonist naltrindole would suggest that the analgesia induced by 
high-frequency TENS in our group of participants was subserved by the δ opioid receptor 
[15;25], the impossibility to use selective antagonists in human subjects prevents us from 
making any clear assertion. 
 
Conclusion 
Our results showed that the high – but not the low - dose of naloxone blocked high-
frequency TENS analgesia, indicating that the analgesic effect of this type of stimulation 
involves endogenous opioids.  Manifestly, the insufficient amount of opioid antagonist 
used in the past prevented previous studies from discovering the importance of opioid 
receptors in producing high-frequency TENS analgesia.  Finally, the important reduction 
in TENS analgesia in participants who received saline at their third session (after having 
received naloxone at their first and second session) suggest that previous exposition to 
ineffective treatments can substantially decrease the efficacy of subsequent interventions.  
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This underscores the importance of previous experience on pain relief and reminds the 
clinician about the necessity of maximizing the efficacy of the first treatment. 
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Figures 
 
Figure 1. TENS and thermode application 
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Figure 2.  TENS analgesia experienced during the saline condition (control condition) 
between participants who received (1) saline at their first session, (2) naloxone at their 
first session and saline at their second session and (3) naloxone at their fist and second 
sessions and saline at their third session.   Participants who received saline at their first 
session showed a larger analgesic effect than the other participants. 
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Figure 3. Comparisons of pain intensity measures to thermal stimulation obtained at 
baseline, after injection, during TENS and after TENS.  There was a significant reduction 
in pain intensity both during and after TENS when compared with baseline for the saline 
(p<.01) and low dose condition (p<.05) but not for the high dose condition (p=.20). 
Between-subject analyses comparing pain intensity during TENS across the three groups 
revealed that there was a significant difference during TENS between the saline group 
and the high dose group (p<.01). 
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